论文部分内容阅读
Aims:A novel ligend-PEG-drug conjugate,octreotide-polyethene glycol-paclitaxel (OCT-PEG-PTX) was developed for efficient cancer therapy.Method:The ligand OCT was first conjugated to the carboxyl group of PEG by EDC reaction (OCT-PEG)and then the paclitaxel was conjugated to OCT-PEG by using succinic anhydride as a spacer (OCT-PEG-PTX).Non-targeted prodrug,PEG-PTX,was also synthesized as control.The chemical structures and physicochemical properties were characterized indetail.